PDCD1LG2 and cancer: Other actionable genomic variants included SMARCB1 loss (one patient, 5%), amplification of 9p24.1, which includes PD-L1, PD-L2 and JAK2 (one patient, 5%), and an NRAS p.Q61K mutation (two patients, 10%) (Fig. 3g), although none provided treatment recommendations that matched the patients’ cancer types (Supplementary Table; see Actionable panel sequencing results).